Reuters: Genzyme's Lumizyme faces delay after FDA rejection

[NaDiNe]

Genzyme's Lumizyme faces delay after FDA rejection
      
   
      

NEW YORK (Reuters) - U.S. regulators have declined to approve Genzyme Corp's new Lumizyme treatment for Pompe disease, a setback the drugmaker said could delay its approval for six months and crimp 2009 earnings.<div class="feedflare">
You are not allowed to view links. Register or Login You are not allowed to view links. Register or Login You are not allowed to view links. Register or Login
</div><img src="You are not allowed to view links. Register or Login" height="1" width="1"/>
      

You are not allowed to view links. Register or Login